Papel da suplementação oral de Bifidobacterium longum 51A no tratamento preventivo da dermatite de contato alérgica experimental
Data
2019-06-24
Autores
Queiroz, André Garcia 
Orientadores
Ferreira, Caroline Marcantonio
Tipo
Trabalho de conclusão de curso
Título da Revista
ISSN da Revista
Título de Volume
Resumo
A dermatite de contato alérgica (DCA) é uma inflamação de pele caracterizada por hipersensibilidade tipo IV, mediada por linfócitos T. Entre seus sintomas estão: lesões cutâneas, ressecamento da pele, vermelhidão, edema e prurido intenso. A intervenção farmacológica é feita através de glicocorticoides tópicos, ou em casos mais graves, glicocorticoides sistêmicos. Estes fármacos comumente apresentam efeitos adversos, como estrias e atrofia da pele. Ainda não há disponível um tratamento eficaz e menos agressivo para a DCA. Este trabalho teve como objetivo a avaliação da bactéria probiótica produtora de acetato Bifidobacterium longum 51A (BL51A), como um tratamento preventivo para a DCA, através de um modelo murino de DCA induzida por oxazolona e averiguação de parâmetros biofísicos relacionados à DCA, além de dosagem de citocinas nos grupos de tratamento com gavagem de BL51A, BL51A inativada e acetato via intraperitoneal. Os tratamentos com BL51A e com acetato tiveram êxito em reduzir a inflamação neste modelo, mas não o tratamento com BL51A inativada. O perfil de citocinas dos grupos tratados com BL51A e com acetato foi diferente, sugerindo que a produção de acetato não é o único mecanismo através do qual este probiótico exerce sua ação preventiva contra a DCA.
Allergic contact dermatitis (ACD) is a skin inflammation characterized by type IV hypersensibility, mediated by T cells. Among its symptoms, there is skin dryness, lesions, redness, edema, and intense pruritus. The pharmacological intervention is made through topic glucocorticoids or systemic glucocorticoids, in more severe cases. These drugs commonly cause adverse effects, such as stretch marks and skin atrophy. There is no effective and less aggressive treatment for ACD described yet. This work had the purpose to evaluate the action of the acetate-producing probiotic Bifidobacterium longum 51A as a preventive treatment for ACD, through an oxazolone-induced murine model and assessment of biophysical parameters related do DCA and cytokine dosage of the groups treated with BL51A gavage, inactivated BL51A, and acetate administered via intraperitoneal. The groups treated with BL51A and acetate were successful in decreasing the inflammation in this model, while the treatment with inactivated BL51A was ineffective. The cytokine profile of the groups treated with BL51A and acetate was different, suggesting that acetate production is not the only mechanism through which this probiotic plays its preventive role against ACD.
Allergic contact dermatitis (ACD) is a skin inflammation characterized by type IV hypersensibility, mediated by T cells. Among its symptoms, there is skin dryness, lesions, redness, edema, and intense pruritus. The pharmacological intervention is made through topic glucocorticoids or systemic glucocorticoids, in more severe cases. These drugs commonly cause adverse effects, such as stretch marks and skin atrophy. There is no effective and less aggressive treatment for ACD described yet. This work had the purpose to evaluate the action of the acetate-producing probiotic Bifidobacterium longum 51A as a preventive treatment for ACD, through an oxazolone-induced murine model and assessment of biophysical parameters related do DCA and cytokine dosage of the groups treated with BL51A gavage, inactivated BL51A, and acetate administered via intraperitoneal. The groups treated with BL51A and acetate were successful in decreasing the inflammation in this model, while the treatment with inactivated BL51A was ineffective. The cytokine profile of the groups treated with BL51A and acetate was different, suggesting that acetate production is not the only mechanism through which this probiotic plays its preventive role against ACD.